Connection
Michele Fox to Purpura, Thrombotic Thrombocytopenic
This is a "connection" page, showing publications Michele Fox has written about Purpura, Thrombotic Thrombocytopenic.
|
|
Connection Strength |
|
 |
|
 |
|
0.541 |
|
|
|
-
Pandey S, Cottler-Fox M. ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma. Ann Clin Lab Sci. 2018 May; 48(3):373-376.
Score: 0.306
-
Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4.
Score: 0.235